Versuchen GOLD - Frei
Why IPO Pops Don't Tell the Whole Story
Mint Mumbai
|September 11, 2025
Up and Down IPO listing gains have been uneven: 9.1% in May, 10.8% in June, 15.6% in July, and 10.6% in August.
India's benchmark Nifty 50 index has been on a steady climb since April despite the US's tariff pressures and other macroeconomic issues, but initial public offerings (IPOs) have struggled to deliver consistent listing-day returns to investors.
Listing day is when a firm's shares debut on the stock exchanges following an IPO. The difference between the share price on listing day and the price at which the shares were sold during the IPO is keenly watched, especially by investors who have bet their money on the firm's growth.
Average listing-day returns have swung from 9.1% in May to 10.8% in June, 15.6% in July, and 10.6% in August, show data from Prime Database.
And while the Nifty 50 has gained 5.2% so far in 2025 (as of 9 September), the Nifty IPO index has declined 1.2%, per Capitaline data.
How important are listing-day returns for investors? Mint explains.
What factors influence listing-day returns?
Listing-day returns are driven by a wider set of factors than just the market's trajectory, said Hari Shyamsunder, vice president and senior institutional portfolio manager at Franklin Templeton Emerging Markets Equity, India.
Diese Geschichte stammt aus der September 11, 2025-Ausgabe von Mint Mumbai.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

